Drug Profile
Research programme: BAK gene therapies - Introgen
Latest Information Update: 18 Feb 2010
Price :
$50
*
At a glance
- Originator LXR Biotechnology
- Developer Introgen Therapeutics
- Class Gene therapies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Sep 2003 Preclinical trials in Cancer in USA (Parenteral)
- 12 Apr 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 14 Dec 1998 Preclinical development for Cancer in USA (Unknown route)